Redhill Biopharma Ltd. RDHL shares are trading higher Wednesday after the company was granted a patent for a method for eradicating helicobacter pylori infections in patients regardless of body mass index.
The Details:
Redhill Biopharma shares are moving on above-average trading volume Wednesday. According to data from Benzinga Pro, more than 7.27 million shares have already been traded in the session, compared to the stock’s 100-day average of 9.125 million shares.
In late December, RedHill Biopharma announced that two of its investigational drugs, opaganib and RHB-107 (upamostat), demonstrated robust synergistic effect when combined individually with remdesivir (Veklury), in a U.S. Army-funded and conducted Ebola virus in vitro study.
“Opaganib and RHB-107 are both novel, oral, host-directed, small molecule investigational drugs with demonstrated activity against multiple viral targets, including COVID-19, and are expected to be effective against emerging viral variants. This, together with their growing safety and tolerability databases, presents a compelling hypothesis for further study of their potential in treating Ebola virus,” said Reza Fathi, Ph.D., senior vice president of research and development at RedHill.
Related News: What’s Going On With Spirit Airlines Stock?
RDHL Price Action: According to Benzinga Pro, RedHill Biopharma shares are up 22% at $1.09 at the time of publication.
Image: Emilian Danaila from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
